Celecoxib Teva is commonly used across conditions presenting with chronic, sustained inflammation, such as Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS). It may assist with easing symptom clusters involving persistent joint pain, swelling, and stiffness. This provides support that helps ease the overall symptom burden and contributes to easing day-to-day comfort for those managing these chronic manifestations.

It is also relevant in clinical settings where supportive symptom management is appropriate for sudden, time-limited discomfort. This includes being used for managing general acute pain from various sources, and is applied in situations involving recurrent episodic pain such as painful Primary Dysmenorrhea and the discomfort of Acute Migraine Headaches. It is commonly used to help with symptoms in pediatric patients with Juvenile Idiopathic Arthritis (JIA).

“The symptomatic support offered by this medication is relevant across acute therapeutic contexts, especially where symptoms interfere with daily stability.”

---

Quick Fact Block

Property	Description
Quick Fact: Support for	Joint Pain and Inflammatory Swelling
Primary Scenarios	Support for Chronic Arthritis Symptoms and Acute Pain Episodes
Key Indications	OA, RA, AS, JIA, acute pain, primary dysmenorrhea

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility for Celecoxib Teva: Official Regulatory Information

Contraindicated Populations

Celecoxib Teva must not be used by patients with:

• Known hypersensitivity to celecoxib, any excipients, or sulfonamides.
• A history of allergic-type reactions (e.g., asthma, urticaria) after taking aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).
• Active peptic ulceration, GI bleeding, or Inflammatory Bowel Disease.
• Severe congestive heart failure (NYHA Class II-IV or III-IV) or established ischaemic heart disease (EU labeling).
• Severe hepatic dysfunction (Child-Pugh Class C) or severe renal insufficiency (CrCl lt 30 ml/min).
• The setting of Coronary Artery Bypass Graft (CABG) surgery.

Age and Physiological Limitations

• Pediatric Use: The medicine is approved for Juvenile Idiopathic Arthritis (JIA) in patients 2 years of age and older. Safety and efficacy are not established below the age of 2 years.
• Pregnancy: It is contraindicated in women who are pregnant or may become pregnant (EMA) and must be avoided from 30 weeks of gestation onward (FDA).
• Lactation: Use is contraindicated during breastfeeding (EMA).

Restricted Use

Use requires caution or dosage adjustment for patients with moderate hepatic impairment (Child-Pugh Class B) and in patients who are known or suspected CYP2C9 poor metabolizers.

Interactions with other medicines and products

Celecoxib Teva has documented pharmacokinetic and pharmacodynamic interactions requiring specific cautions or restrictions as stated in regulatory prescribing information.

---

Contraindicated and High-Risk Combinations

Co-administration with other Non-Aspirin Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or Salicylates is generally not recommended due to an increased risk of serious gastrointestinal toxicity. Use is formally prohibited in patients with known sulfonamide hypersensitivity or a history of allergic reactions to aspirin or other NSAIDs. The medicine is also contraindicated for the treatment of pain following Coronary Artery Bypass Graft (CABG) surgery. Concomitant use with Warfarin or other anticoagulants carries a heightened risk of serious bleeding events.

---

Metabolic and Concentration Effects

Celecoxib is primarily metabolized by the CYP2C9 enzyme. Co-administration with the inhibitor Fluconazole results in increased plasma exposure of celecoxib. Conversely, co-administration with an inducer like Rifampin may reduce exposure. Celecoxib may also increase the plasma concentration of drugs metabolized by CYP2D6. Furthermore, celecoxib can increase serum levels of Lithium and Digoxin due to reduced renal clearance, and increases the toxicity risk of Methotrexate.

---

Pharmacodynamic Effects

Celecoxib may diminish the antihypertensive effect of ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), and Beta-Blockers. It may also reduce the natriuretic effect of Diuretics. This combination carries a specific risk of deterioration of renal function in elderly or renally impaired patients. Administration with a high-fat meal results in a delay in peak plasma levels and a small increase in total absorption.

Selective Inhibition of the COX-2 Enzyme

Celecoxib Teva operates by the mechanism of selective inhibition against the Cyclooxygenase-2 ( COX-2) enzyme, which is inducible following tissue perturbation. This molecular targeting prevents the enzyme from initiating the synthesis of pro-inflammatory chemical messengers, thereby reducing the activity of this specific biological pathway.

---

Modulation of Prostaglandin Signaling

The inhibition of COX-2 results in a sharp reduction of lipid mediators, such as PGE2, that mediate nociceptive signaling and inflammatory pathways. This mechanistic cascade directly decreases the chemical sensitization of nociceptors and alters the physiological processes that are associated with vasodilation and increased capillary permeability.

---

Physiological Selectivity and Mechanistic Constraints

A defining feature of this mechanism is the maintenance of high COX-2 selectivity and minimal activity against the COX-1 enzyme at therapeutic concentrations. This focus on the inducible COX-2 pathway maintains the functions mediated by COX-1, such as those mediated by COX-1 in the gastrointestinal mucosa, and does not inhibit COX-1-driven platelet aggregation.

Celecoxib Teva is administered exclusively via the oral route as a capsule, strictly following the dosage and administration instructions. The general principle across all indications is to use the lowest effective dosage for the shortest duration possible.

Standard Adult Dosing Regimens

Dosing regimens are highly specific to the condition for which the medicine is used. The daily maximum dose for chronic conditions like Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS) is 400 mg.

Indication	Starting / Maintenance Dose	Frequency Pattern
Osteoarthritis (OA)	200 mg per day (as single or divided doses)	Once Daily (QD) or Twice Daily (BID)
Rheumatoid Arthritis (RA)	100 mg to 200 mg	Twice Daily (BID)
Acute Pain & Primary Dysmenorrhea	400 mg initial dose, followed by 200 mg as needed on day one. Subsequent days: 200 mg	Twice Daily (BID) as needed

For chronic arthritis indications, such as AS, if no benefit is observed after six weeks on the initial dose, a trial of 400 mg daily may be considered.

Administration and Special Populations

Celecoxib capsules can be taken with or without food. For individuals who experience difficulty swallowing, the entire contents of the capsule can be carefully emptied onto a level teaspoon of applesauce, rice gruel, yogurt, or mashed banana. The mixture must be ingested immediately with water to ensure the full dose is administered.

Dose reduction is explicitly mandated for certain patient groups. For adults with moderate hepatic impairment (Child-Pugh Class B), the starting dose must be reduced by 50% of the lowest recommended dose. For pediatric patients aged 2 years and older with Juvenile Idiopathic Arthritis (JIA), the dose is determined based on body weight. If a dose is missed, it should be taken as soon as it is remembered, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped.

Research Evidence / Overview of Studies for Celecoxib Teva

The research base for Celecoxib Teva, which contains the active ingredient celecoxib, is derived from large clinical evaluation programs reviewed by regulatory authorities. This evidence describes the research conducted across the studied indications, according to high-quality trials and scientific reviews.

---

Evidence for Use in Chronic Joint Conditions

This section will summarize the research describing the evaluation of celecoxib in chronic conditions, including Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS). It will detail the types of large-scale Randomized Controlled Trials (RCTs) and systematic reviews that were conducted and what measures of pain and function these studies examined.

Study Focus: Osteoarthritis and Rheumatoid Arthritis

Researchers used numerous short-term RCTs and meta-analyses to evaluate celecoxib in adults with OA and RA who were included in trials. These studies monitored patient-reported outcomes related to perceived discomfort and daily functioning or activity level. For OA, studies explored how symptoms evolved in the observed populations by measuring changes in standardized scales like the WOMAC Index. For RA, research focused on specific changes in disease activity, tracking whether patients met certain criteria for improvement (ACR response criteria).

Study Focus: Ankylosing Spondylitis

For Ankylosing Spondylitis (AS), research also relies on RCTs designed to examine symptom changes. Studies monitored outcomes linked to inflammatory or irritative states using specialized tools like the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Compared to OA and RA, the evidence base for AS involves fewer large-scale long-term comparative studies, and certainty remains low regarding sustained outcomes beyond the intermediate study duration.

---

Long-Term Studies and Extended Follow-up Data

While many efficacy trials were short, research for celecoxib includes several major, multi-year studies that monitored patterns over extended periods, sometimes for more than two and a half years. These large trials were primarily applied in observational settings evaluating daily-life functioning and focused on collecting data related to specific long-term outcomes monitored during extended exposure. The persistence of symptomatic change over long periods is not the primary subject of these outcomes trials.

---

Evidence in Special Populations

Celecoxib was evaluated in pediatric patients aged 2 years and older included in trials for Juvenile Idiopathic Arthritis (JIA). These studies typically monitored responses over defined time intervals, such as 12 to 24 weeks, using JIA-specific clinical response criteria. While findings describe patterns observed in these studies, research provides insight into short-term changes, and the data for certain groups (e.g., long-term outcomes into adulthood) remain insufficient.

Key Studies & References

1. A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis (NCT00807846)
2. Celecoxib for Rheumatoid Arthritis - Cochrane Systematic Review Summary

Common questions about Celecoxib Teva (FAQ)

---

Q: How quickly should I expect to feel pain relief from Celecoxib Teva?

A: Studies conducted on the active ingredient indicate that for treating acute pain, relief may begin within 60 minutes of taking a single dose. For chronic conditions like Osteoarthritis, patients typically report seeing significant reductions in pain after starting a regular dosing schedule for 24 to 48 hours.

---

Q: How long does the pain-relieving effect of Celecoxib Teva typically last?

A: Official product information, which details how the medicine is processed in the body, indicates that the active substance has an elimination half-life of approximately 8 to 12 hours. This duration is a key factor in determining why the medicine is often taken once or twice daily to maintain its therapeutic effect.

---

Q: Does Celecoxib Teva thin your blood?

A: No. Official documents state that Celecoxib Teva is a selective COX-2 inhibitor, meaning it is not expected to significantly interfere with the COX-1 enzyme responsible for platelet function and blood clotting. However, regulatory warnings state that combining this medicine with blood thinners like warfarin is associated with an increased risk of bleeding events.

---

Q: What happens if I forget to take a dose of Celecoxib Teva?

A: If a dose is missed, regulatory instructions generally state to take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the regulatory instruction is to skip the missed dose and resume the normal schedule. Taking a double dose is not advised.

---

Q: Can taking Celecoxib Teva make me feel dizzy or drowsy?

A: Official reports on side effects classify dizziness as a common event for the active ingredient. While drowsiness is not typically listed as a frequent side effect, any medicine that affects the central nervous system may cause some feeling of impairment. Due to the potential for dizziness, performing tasks that require concentration, such as driving or operating machinery, may require caution.

---

Q: Is there a risk of addiction or dependence with Celecoxib Teva?

A: No. Celecoxib Teva is classified as a Nonsteroidal Anti-inflammatory Drug ( NSAID). According to regulatory standards, this class of medicine is not considered a controlled substance and does not carry a known risk of addiction or physical dependence.

---

Q: Does Celecoxib Teva affect the results of blood tests?

A: Yes, it can. Official safety information indicates that the drug may lead to elevations in liver enzyme levels, and it has also been associated with anemia, both of which are measurable in blood tests. It is standard practice for patients to inform their healthcare providers about all medicines being taken prior to any blood work.

---

Q: What is the maximum amount of time a person should take Celecoxib Teva for?

A: While the medicine is approved for the long-term management of chronic conditions, official regulatory advice emphasizes using the lowest effective dosage for the shortest duration possible. This approach is recommended because the risk of serious side effects, particularly cardiovascular and gastrointestinal events, is generally stated in official documentation to increase with a longer duration of use.

---

Q: Can Celecoxib Teva be used for treating migraines?

A: The Celecoxib Teva capsule formulation is generally indicated for conditions like arthritis and acute pain. However, a different formulation containing the same active ingredient, celecoxib, has received FDA approval for the acute treatment of migraine in adults.

---

Q: Can young adults or teenagers take Celecoxib Teva for sports injuries?

A: Official labeling permits the use of this medicine only for Juvenile Idiopathic Arthritis ( JIA) in patients aged 2 years and older. Its use for acute pain, such as sports injuries, is only officially labeled and studied for the adult population.

---

Q: Does Celecoxib Teva help with muscle spasms or primarily joint pain?

A: The medicine is primarily indicated for inflammatory conditions like Osteoarthritis and Rheumatoid Arthritis, which involve joint pain. Because it reduces pain and inflammation by blocking prostaglandins, it can help alleviate discomfort in soft tissues, including muscles, but it is not an officially labeled treatment for muscle spasms.

---

Q: How long after stopping Celecoxib Teva does it stay in your system?

A: Based on pharmacokinetics, the elimination half-life is approximately 8 to 12 hours. It generally takes about five half-lives for the drug to be considered almost completely cleared from the system, meaning the active substance is expected to be almost entirely cleared from the system within a few days.

---

Q: Is it normal to have slight changes in mood or sleep when starting Celecoxib Teva?

A: Official side effect classifications note anxiety as an uncommon event associated with the active ingredient. While the labels do not detail broader mood or sleep changes, any unusual psychological changes should be reported to a healthcare professional.

---

Q: Is Celecoxib Teva available over-the-counter anywhere?

A: No. Celecoxib Teva is officially classified as a prescription-only medicine in the United States and is not approved for over-the-counter ( OTC) sales.

---

Q: Is there a risk of liver damage from taking Celecoxib Teva long-term?

A: Yes. Regulatory documents carry a warning about hepatotoxicity (liver damage), which can potentially be fatal. Patients are generally advised to be aware of possible warning signs, such as nausea, unusual fatigue, or yellowing of the skin (jaundice), and to seek immediate medical attention if they appear.

---

Q: Can Celecoxib Teva interact with depression or anxiety medications?

A: Official interaction warnings note that taking NSAIDs along with certain other medicines can increase the risk of bleeding. This includes common classes of depression and anxiety medications, such as SSRIs (Selective Serotonin Reuptake Inhibitors). This highlights the importance of healthcare providers having a complete list of all medications being taken.

Official Storage and Disposal Requirements

Celecoxib capsules must be stored within a specific temperature range to ensure product stability. The required storage condition is 25 C (77 F), with permitted temperature excursions between 15 C and 30 C (59 F and 86 F). The medication must be kept out of the reach of children.

Handling Detail	Requirement
Child Safety	Store out of the reach of children
Prepared Mixture Stability	Use immediately, or store refrigerated for up to 6 hours

If the capsule contents are mixed with applesauce for administration, the resulting mixture is stable for a maximum of six hours only when stored under refrigerated conditions (2-8 C). Official regulatory labeling does not provide specific instructions for household disposal of unused or expired Celecoxib Teva; therefore, the product should be disposed of through a drug take-back program or by consulting a pharmacist.